Pfizer Inc Chief Executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.
Chief Executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.COVID-19 vaccine has shown to be effective against severe disease and death caused by the heavily-mutated Omicron variant but less effective in preventing transmission.
"This will not be a good scenario. What I'm hoping that we will have a vaccine that you will have to do once a year," Bourla said.Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.
Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Annual COVID vaccine preferable to boosters, says Pfizer CEO'What I'm hoping (is) that we will have a vaccine that you will have to do once a year,' Bourla said.
Lire la suite »
Pfizer COVID-19 Vaccine for Kids Under 5 Could be Authorized Soon: OfficialsPediatricians say the omicron surge has been especially hard on children and there may be relief soon for those under 5.
Lire la suite »
Third Dose of Pfizer, Moderna Covid-19 Vaccines Offers Strong Protection Against OmicronCDC analysis shows that boosters are important in maximizing protection against Omicron and Delta variants.
Lire la suite »
Bay Area job market soars to big gains in December, defies COVID surgeThe Bay Area added jobs at a brisk pace in December, ending 2021 on a bright note that defied the fresh economic uncertainties unleashed by the omicron variant of the coronavirus.
Lire la suite »
FDA acts to expand use of treatment for COVID-19 patients with mild-to-moderate diseasePreviously, the use of Veklury, a Gilead Sciences Inc. drug, was limited to those requiring hospitalization.
Lire la suite »
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severityUnlike antibodies elicited by mRNA vaccines against COVID19, some non-neutralizing, afucosylated IgG antibodies specific to SARSCoV2 may be associated with progression to more severe disease, according to new research in ScienceTM.
Lire la suite »